I think CXA-201 is far more important for CBST. Anti Gram-negative infections drugs area is not as crowded as c. difficile infections and a much bigger one plus CBST is leading the pack especially for multi-drug resistant Gram-negative pathogens like pseudomonas aeruginosa, which is the most common one. In the c. difficile infections it is not clear if CB-183,315 will have an advantage in NAP-1 strains or have better reduction in recurrence rate than other CDAD products.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.